Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 04, 2018 16:06 ET | Source: Aduro Biotech, Inc.

Aduro Biotech and Dana-Farber Cancer Institute Publish Data Highlighting Immunosuppressive Impact of APRIL in Multiple Myeloma in Leukemia

BERKELEY, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced the publication of a peer reviewed paper in Leukemia authored by scientists from the Dana...
September 04, 2018 16:01 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Presents Preclinical Data for BION-1301, a First-in-Class Antibody Targeting Human APRIL, at the 2018 European Congress of Immunology

BERKELEY, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that preclinical data for its first-in-class anti-APRIL antibody BION-1301 was presented at the...
August 29, 2018 16:01 ET | Source: Aduro Biotech, Inc.

Aduro Biotech to Present at the 20th Annual H.C. Wainwright Global Investment Conference

BERKELEY, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present...
August 22, 2018 16:01 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Granted Composition of Matter Patent for Novel Human APRIL Binding Antibodies

BERKELEY, Calif., Aug. 22, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that the United States Patent and Trademark Office has issued a new composition of matter...
August 01, 2018 16:01 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Reports Second Quarter 2018 Financial Results

BERKELEY, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today reported financial results for the second quarter ended June 30, 2018. Net loss for the second quarter of...
June 07, 2018 16:01 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Announces Initiation of Phase 1b Clinical Trial in Non-Small Cell Lung Cancer under Janssen Strategic Partnership for ADU-214 in Combination with Nivolumab

BERKELEY, Calif., June 07, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced the recent initiation of a Phase 1b study of ADU-214 (JNJ-64041757) in combination with...
May 10, 2018 16:01 ET | Source: Aduro Biotech, Inc.

Aduro Biotech to Present at the Bank of America Merrill Lynch 2018 Health Care Conference

BERKELEY, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at...
May 02, 2018 16:01 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Reports First Quarter 2018 Financial Results

BERKELEY, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today reported financial results for the first quarter ended March 31, 2018. Net loss for the first quarter of...
April 26, 2018 08:00 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Presents Early Observations From its Personalized Neoantigen-based pLADD Therapy Clinical Study at European Neoantigen Summit

BERKELEY, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today presented preliminary observations from a case study of a patient with metastatic colorectal cancer...
April 17, 2018 16:01 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Highlights Preclinical Data for Three Programs Reported at the American Association for Cancer Research Annual Meeting

BERKELEY, Calif., April 17, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that data from three of the company’s programs were presented at the American Association for...